---
created: 2025-04-13
updated: 2025-04-13T10:53
id: tp:_P2xUAQ
specialty: patho
specialty_id: 63
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::08-endocrinology::05-other::04-signaling-pathways
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::*basics
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::08-oncogenes
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::08-oncogenes::growth-factors::*basics
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::07-endocrinology
  - "source/ak-step1-v11:": 
  - theme/physeo::11-pathology::07-general-pathology::09-carcinogenesis
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::smallmoleculeinhibitors(tyrosinekinase-proteasomeinhibitors-cdkinhibitors)
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::8000-8999::8540
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Tyrosine kinase inhibitors work by targeting downstream signaling pathways involved in growth - the most important being:   - **PI3K/Akt** = increased **BCL-2::proto-oncogene** expression (anti-apoptosis) == CLL - **JAK/STAT** = increased cell **proliferation** == myeloproliferative disorders (eg, ET, PV, 1ry Mfib) - **RAS/MAPK** = increased cell **growth** - **Src/FAK** = increased cell **motility (invasion)** and decreased cell **adhesion (migration)**

---

# Answer
